{"id":"W4213230310","doi":"10.1200/jco.20.02363","title":"Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Pembrolizumab; Renal cell carcinoma; Oncology; Internal medicine; Open label; Phases of clinical research; First line therapy; Chemotherapy; Immunotherapy; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001770041,0.001356859,0.002197493,0.0004410094,0.000464433,0.001028833,0.0007616647,0.001116884,0.003352261],"category_scores_gemma":[0.001036953,0.000679092,0.0008511198,0.0003586438,0.0009369909,0.001111703,0.0003594565,0.00330496,0.001051978],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009390456,"about_ca_system_score_gemma":0.001823021,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006818371,"about_ca_topic_score_gemma":0.001863483,"domain_scores_codex":[0.9994782,0.0002214239,0.00002770447,0.0001145243,0.00006739936,0.00009075666],"domain_scores_gemma":[0.9990387,0.0001237963,0.0001633492,0.00007364242,0.00007731516,0.0005231907],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6614399,0.2114664,0.01152298,0.0007810976,0.001245605,0.0002899121,0.0004456596,0.001605694,0.03869129,0.0001970494,0.003574354,0.06874005],"study_design_scores_gemma":[0.5796461,0.3999497,0.01537429,0.00002386502,0.0002073077,0.0002134078,0.00005819136,0.001089967,0.001690415,0.0001131096,0.001610977,0.00002267566],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994023,0.001232421,0.000391497,0.0002725541,0.00009095034,0.00234781,0.0006743606,0.00005693209,0.0009103559],"genre_scores_gemma":[0.9904378,0.00089564,0.001521139,0.0007463019,0.0002098517,0.002785125,0.001563424,0.00001922906,0.001821627],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003352261,"threshold_uncertainty_score":0.01121444,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1270295961272147,"score_gpt":0.4285247223605393,"score_spread":0.3014951262333247,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}